The patent applications concern its proprietary formulation technologies for its products TX12001HR, TX12002HR and TX12003HR.
TherapeuticsMD CEO Robert Finizio said, "The submission of these patents marks a new platform for Therapeutics’ expansion in the women’s health market."
The company expects to begin trials for the prescription products shortly and hence aims to seek FDA approval under a new drug approval for the products as early as 2013 and as late as 2015.